L

LTR Pharma Ltd
ASX:LTP

Watchlist Manager
LTR Pharma Ltd
ASX:LTP
Watchlist
Price: 0.725 AUD -4.61% Market Closed
Market Cap: 111.5m AUD
Have any thoughts about
LTR Pharma Ltd?
Write Note

LTR Pharma Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LTR Pharma Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
L
LTR Pharma Ltd
ASX:LTP
Cash Interest Paid
-AU$420
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash Interest Paid
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Cash Interest Paid
-AU$6m
CAGR 3-Years
-40%
CAGR 5-Years
-37%
CAGR 10-Years
-15%
Arovella Therapeutics Ltd
ASX:ALA
Cash Interest Paid
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LTR Pharma Ltd
Glance View

Market Cap
101.1m AUD
Industry
Pharmaceuticals

LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

LTP Intrinsic Value
0.008 AUD
Overvaluation 99%
Intrinsic Value
Price
L

See Also

What is LTR Pharma Ltd's Cash Interest Paid?
Cash Interest Paid
-420 AUD

Based on the financial report for Jun 30, 2024, LTR Pharma Ltd's Cash Interest Paid amounts to -420 AUD.

What is LTR Pharma Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 1Y
-2 000%

Over the last year, the Cash Interest Paid growth was -2 000%.

Back to Top